PHILADELPHIA — Medications that reduce blood pressure and improve glycemia may preserve kidney function over time despite initial eGFR dips, according to a speaker at the Heart in Diabetes CME Conference.Matthew R. Weir, MD, professor and chief in the division of nephrology at University of Maryland School of Medicine, said eGFR dips “should be expected and planned upon” when using BP-lowering medications and should not deter clinicians from using them.“An eGFR dip is cause of concern when it is more than 30%,” Weir told Healio. “But you have to carefully
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Combination GLP-1 and SGLT2 therapy may lower heart risk | 0 | 5 | 25-06-2026 |
| 2 | Recent policy changes impact ‘cardiometabolic care cascade’ | 0 | 7 | 30-06-2026 |
| 3 | IgA nephropathy treatment decisions vary among physicians | 0 | 7 | 01-07-2026 |
| 4 | Respiratory failure, CKD-related mortality rose in 1999-2021 | 0 | 7 | 26-06-2026 |
| 5 | Some adverse pregnancy outcomes tied to kidney donation | 0 | 7 | 30-06-2026 |
| 6 | Prioritize risk reduction for people with diabetes using CGM | 5 | 7 | 26-06-2026 |
| 7 | How a rare kidney disease gained a robust new therapy pipeline | 3 | 7 | 24-06-2026 |
| 8 | Obesity presents differently for men compared with women | 0 | 5 | 01-07-2026 |
| 9 | Understanding environment in cardiometabolic risk | 0 | 5 | 29-06-2026 |
| 10 | Кардиолог Бойцов: Летальность инфаркта в РФ должна уменьшиться до 9% к 2030 году | 0 | 5 | 01-07-2026 |